期刊文献+

阿比特龙工艺杂质研究 被引量:2

The Research of Process Impurities of Abiraterone
下载PDF
导出
摘要 为控制阿比特龙质量,分别以去氢表雄酮和二乙基(3-吡啶基)硼烷为起始物料,经过缩合、碘代、Suzuki偶联反应得到阿比特龙。生产过程中易产生工艺杂质A、杂质B、杂质C、杂质D、杂质E及杂质F,通过核磁及质谱对杂质进行结构确证,并对杂质产生的原因进行分析,为阿比特龙工业化生产提供技术支持。 To control the quality of Abiraterone, dehydroepiandrosterone and diethyl(3-pyridyl) borane were used as starting materials. After condensation, iodine, and Suzuki coupling reactions, abiraterone was obtained. During the production process, process impurities A, B, C, D, E, and F were easily generated. The structure of the impurities was confirmed by NMR and mass spectrometry, and the causes of the impurities were analyzed. It provides technical support for Abiraterone industrial production.
作者 袁小明 江德福 刘伟锋 欧阳婷 付敏 YUAN Xiao-ming;JIANG De-fu;LIU Wei-feng;Ouyang Ting;FU Min(Jiangxi Qingfeng Pharmaceutical Co.,Ltd.,Ganzhou,Jiangxi 341000,China;Jiangxi Kewei Collaborative Innovative Pharmaceutical Co.,Ltd.,Ganzhou,Jiangxi 341000,China)
出处 《浙江化工》 CAS 2020年第2期7-10,共4页 Zhejiang Chemical Industry
基金 江西省创新驱动“5511”工程资助项目(20165ABC28011)
关键词 SUZUKI偶联 去氢表雄酮 阿比特龙 二乙基(3-吡啶基)硼烷 Suzuki coupling dehydroepiandrosterone Abiraterone diethyl(3-pyridyl) borane
  • 相关文献

参考文献4

二级参考文献48

  • 1邵常霞,项永兵,刘振伟,高静,孙璐,方茹蓉,阮志贤,高立峰,金凡,高玉堂.上海市区泌尿系统恶性肿瘤相对生存率分析[J].中国肿瘤临床,2005,32(6):321-324. 被引量:31
  • 2叶定伟.前列腺癌的流行病学和中国的发病趋势[J].中华外科杂志,2006,44(6):362-364. 被引量:168
  • 3Scher HI, Sawyers CL. Biology of progressive, castration - resistant prostate cancer: directed therapies targeting the androgen - recep- tor signaling axis. I Clin Oneo1,2005 ,23 :8253 - 8261.
  • 4Attard G, Belldegrun AS, de Bono JS. Selective blockade of an- drogenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int,2005,96: 1241 - 1246.
  • 5Barrie SE, Haynes BP Potter GA, et al. Biochemistry and pharma-cokinetics of potent nonsteroidal cytochrome P450 (17alpha) in- hibitors. J Steroid Biochem Mol Biol, 1997,60 : 347 - 351.
  • 6Jarman M, Barrie SE, Llera JM. The 16,17 -double bond is nee- ded for irreversible inhibition of human cytoehrome p45017alpha by abiraterone ( 17 - ( 3 - pyridyl ) androsta - 5, 16 -dien - 3beta- ol) and related steroidal inbibitors. J Med Chem, 1998, 41 : 5375 -5381.
  • 7Attard G, Reid AH, A "Hem R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration - resistant prostate cancer. J Clin Oneol, 2009,27: 3742 - 3748.
  • 8Attard G, Reid AH, Yap TA, et al. Phase t clinical trial of a se- lective inhibitor of CYP17, abiraterone acetate, confirms that cas- tration - resistant prostate cancer commonly remains hormone driv- en. J Clin 0ncol,2008,26 : 4563 -4571.
  • 9Danila DC, Morris M J, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel - treated castration - resistant prostate cancer. J Clin Onco1,2010,28 : 1496 - 1501.
  • 10Reid AH, Attard G, Danila DC, et al. Significant and sustained antitumor activity in post - docetaxel, castration - resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol, 2010,28:1489 - 1495.

共引文献130

同被引文献7

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部